Peter MD vs Sesame Care
Two GLP-1 desks, one scoreboard. We put Peter MD and Sesame Care head-to-head on the published Brief Score — the same six factors, scored the same way.
Sesame Care
The verdict
Sesame Care takes this head-to-head.
Sesame Care scores 87 to 76 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.
That doesn't make Peter MD a bad call — it's best for readers who want glp-1 care bundled with trt, sermorelin, nad+ or hair-loss treatment on a single account, and are comfortable reading a tiered price ladder rather than one flat monthly figure this site can map straight onto a dose. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Peter MD | Sesame Care | |
|---|---|---|
| Brief Score | 76/100 (C) | 87/100 (B+) |
| Semaglutide | $149/mo new-user tier · $139/mo returning-user tier (GLP1 + B12) | From $149/mo (brand Wegovy pill) |
| Tirzepatide | $249/mo after a $149 first month (billed quarterly, 60mg) | Brand Zepbound (price varies) |
| Coverage | Most states — exclusions vary by treatment (not a single list) | Nationwide marketplace |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Newnew to the tracker, no prior reading | Stableprice stable |
Peter MD: First reading, 2026-08-04: tirzepatide runs $149 the first month before resetting to $249 on quarterly billing; compounded semaglutide (sold as GLP1 + B12) splits into a $149/mo new-user tier and a $139/mo returning-user tier rather than one flat monthly rate.
Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.